Back to Search Start Over

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia

Authors :
Liuluan Zhu
Yaxian Kong
Jianhong Zhang
David F. Claxton
W. Christopher Ehmann
Witold B. Rybka
Neil D. Palmisiano
Ming Wang
Bei Jia
Michael Bayerl
Todd D. Schell
Raymond J. Hohl
Hui Zeng
Hong Zheng
Source :
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-13 (2017)
Publication Year :
2017
Publisher :
BMC, 2017.

Abstract

Abstract Background T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) and programmed cell death protein 1 (PD-1) are important inhibitory receptors that associate with T cell exhaustion in acute myeloid leukemia (AML). In this study, we aimed to determine the underlying transcriptional mechanisms regulating these inhibitory pathways. Specifically, we investigated the role of transcription factor B lymphocyte-induced maturation protein 1 (Blimp-1) in T cell response and transcriptional regulation of TIGIT and PD-1 in AML. Methods Peripheral blood samples collected from patients with AML were used in this study. Blimp-1 expression was examined by flow cytometry. The correlation of Blimp-1 expression to clinical characteristics of AML patients was analyzed. Phenotypic and functional studies of Blimp-1-expressing T cells were performed using flow cytometry-based assays. Luciferase reporter assays and ChIP assays were applied to assess direct binding and transcription activity of Blimp-1. Using siRNA to silence Blimp-1, we further elucidated the regulatory role of Blimp-1 in the TIGIT and PD-1 expression and T cell immune response. Results Blimp-1 expression is elevated in T cells from AML patients. Consistent with exhaustion, Blimp-1+ T cells upregulate multiple inhibitory receptors including PD-1 and TIGIT. In addition, they are functionally impaired manifested by low cytokine production and decreased cytotoxicity capacity. Importantly, the functional defect is reversed by inhibition of Blimp-1 via siRNA knockdown. Furthermore, Blimp-1 binds to the promoters of PD-1 and TIGIT and positively regulates their expression. Conclusions Our study demonstrates an important inhibitory effect of Blimp-1 on T cell response in AML; thus, targeting Blimp-1 and its regulated molecules to improve the immune response may provide effective leukemia therapeutics.

Details

Language :
English
ISSN :
17568722
Volume :
10
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal of Hematology & Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.58d71e23b53049f58def55e2864a4e4f
Document Type :
article
Full Text :
https://doi.org/10.1186/s13045-017-0486-z